Five-Drug Combination Shows Benefit in Ultra-High Risk Multiple Myeloma

Final data from the UK Optimum trial shows drug combination significantly improves progression-free survival in patients with ultra-high risk newly diagnosed multiple myeloma or primary cell leukaemia.

Related Keywords

United States ,United Kingdom ,London ,City Of ,American ,Martin Kaiser ,American Society Of Hematology ,Institute Of Cancer Research ,Royal Marsden Foundation ,Clinical Trials Research Unit ,University Of Leeds ,Cancer Research ,American Society ,Royal Marsden Foundation Trust ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Hematology Haematology ,Uk Site Content United Kingdom ,Uk ,Leukemia Leukaemia ,Clinical Research ,Clinical Trials ,Linical Studies ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Biologic Therapy ,Iologics ,Immunomodulator ,Lenalidomide ,Proteasome Inhibitor ,Bortezomib ,Toxicology ,Toxicity ,Poisoning ,Toxins ,